KLRK1 and plasma cell myeloma: No myelotoxicity, T-cell toxicity or other autoimmune effects were observed in a recent Phase 1 trial of NKG2D-CAR T cells in adults with AML and multiple myeloma, providing a first reassuring safety signal of this approach in the clinic (40).